Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Trump administration attacks on the National Institutes of Health mean biomedical research will become less ambitious, less ...

However these new approaches, and the arrival of potentially ‘disruptive innovation’ from tech players such as Google and Amazon, mean pharma scientists need to leave their comfort zone more ...

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...

This puts the scientist at the centre of a new suite ... workforce as the top hindrance to digital transformation in the pharmaceutical industry. An increased importance will be placed on the ...

Varda, a US firm planning to manufacture pharmaceuticals in low Earth orbit, is expecting its second capsule to return to Earth this week ...

At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...

Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics ...

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables the precise functionalization of peptides and proteins.